ArticleActa dermato-venereologica2024
Acral Melanoma Incidence and Survival Trends in 1990-2020: A Nationwide, Population-based Study.
Article in Acta dermato-venereologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Risk factors for the development of acral melanoma: A multi-institutional, retrospective cohort study.JAAD international · 2026Article
- Utilizing relative survival to investigate melanoma subtypes across intersectional demographics: a Surveillance, Epidemiology, and End Results (SEER) cohort study.Skin health and disease · 2026Article
- Declining melanoma incidence among younger adults in Sweden: insights from histopathological subtypes and the role of immigration.Acta oncologica (Stockholm, Sweden) · 2026Article
- Enhanced measures of neoantigenicity capture unique tumor-immune interactions across primary melanoma subtypes.Genome medicine · 2026Article
- Comprehensive Genomic Profiling of Acral Melanoma: Insights From the AACR Project GENIE Database.The American Journal of dermatopathology · 2026Article
- mTORC1/2 inhibition induces tumor regression in CDK4/6 inhibitor-insensitive acral melanoma.Cancer gene therapy · 2026Article
- Clinical and Histopathological Prognostic Factors for Disease-Free Survival in Early-Stage Acral and Non-Acral Cutaneous Melanoma: A Retrospective Asian Cohort Analysis.Cancer management and research · 2026Article
- Cardiovascular disease mortality risk among patients with metastatic melanoma before and after the approval of immunotherapy in the United States: a Surveillance, Epidemiology, and End Results database-based study.European journal of medical research · 2025Article
- Targeting Melanoma Cell Adhesion Molecule as a Novel Therapeutic Approach for Acral Melanoma.Experimental dermatology · 2025Article
- MEK inhibitors for the treatment of immunotherapy-resistant, AGK-BRAF fusion advanced acral melanoma: a case report and literature review.Journal of cancer research and clinical oncology · 2025Review
- Multivariate analysis and prediction model construction for distant metastasis of Acral Melanoma.American journal of cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acral melanoma is a clinical subtype of melanoma with high mortality, on which research is limited in scope. This study aimed to assess incidence trends and melanoma-specific survival rates for acral melanoma in the Swedish population from 1990 to 2020.This cross-sectional study included patients with an acral melanoma diagnosis from 1990 to 2020 from the nationwide, population-based Swedish Melanoma Registry. Analyses on acral melanoma melanoma-specific survival rates were adjusted for age, sex, histopathological subtype, and tumour thickness. Clinicopathological features and melanoma-specific survival rates were compared between diagnostic periods: 1990-1999, 2000-2009, and 2010-2020, respectively. Changes in standardized incidence rates in 1996-2020 were evaluated separately for males and females. In total, 1,000 acral melanomas in 999 patients were included in the study. No significant yearly change in standardized incidence rates for either males or females was observed, even though the absolute number of cases increased. Factors such as male sex, age ≥ 70 years, and Breslow thickness > 1.0 were independently linked to lower melanoma-specific survival. The 5-year melanoma-specific survival across the studied period ranged from 75.8% to 77.9% for females, and from 62.4% to 71.7% for males.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.